Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
Active, not recruiting · NCT05071209 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors | Ewing sarcoma, Hemic and Lymphatic Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, alveolar rhabdomyosarcoma, connective tissue neoplasm, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, myomatous neoplasm, neoplasm, osteosarcoma, rhabdomyosarcoma, sarcoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-01-23 | NCT05071209 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute (NCI) | 3015 |
29 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.